Mechanistic insights into the hepatoprotective role of rabeprazole against cyclophosphamide-induced hepatotoxicity via AMPK/SIRT1 activation and suppression of TLR4/NF-κB and MAPK pathways
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-025-04577-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Asmaa Saleh und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, 11671, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Chemical and Drug Induced Liver Injury, Rabeprazole, Cyclophosphamide. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 73 Literaturangaben.
Abstract (Originalsprache)
AIMS: This study evaluates the ability of Rabeprazole (RAB) in counteracting cyclophosphamide (CP)-induced hepatotoxicity, focusing on its regulatory impact on key molecular signaling pathways, particularly AMPK/SIRT1, PI3K/Akt, TLR4/NF-κB, and MAPK, as well as its influence on NLRP3 inflammasome activation. MAIN METHODS: Rats were assigned into four distinct groups (n = 8 each): a control group administered distilled water; a CP group administered a single intraperitoneal dose of CP (200 mg/kg) on the seventh day; and two treatment groups pretreated orally with RAB (10 or 30 mg/kg/day) for ten days, with CP delivered on day 7. Biochemical, histological, immuno-histochemical, qRT-PCR, and western blotting procedures were conducted to evaluate liver function, oxidative status, and molecular signaling. KEY FINDINGS: Rats exposed to CP showed marked increases in hepatic markers (ALT, AST), together with decreases in antioxidative markers (GSH, Nrf2, HO-1) and increases in MDA, MPO, iNOS, as well as pro-inflammatory markers represented by IL-6, TNF-α, IL-1β. Hepatic expression of AMPK, SIRT1, and PI3K/Akt was markedly suppressed, while TLR4, NF-κB p65, MAPK proteins, and NLRP3 were upregulated. RAB pretreatment dose-dependently restored hepatic enzyme levels, corrected redox imbalance, reduced cytokine release, and normalized gene and protein expression profiles. Histopathological improvements further corroborated the protective effect of RAB. SIGNIFICANCE: These results indicate that Rabeprazole may serve as an effective therapeutic option to reduce CP-induced liver injury through its multifaceted protective actions, highlighting the necessity for more extensive research in subsequent studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, 11671, Riyadh, Saudi Arabia.
- Pharmacology and Toxicology Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, 11651, Egypt.
- Department of Clinical Pharmacy, College of Health Sciences and Nursing, Al-Rayan Colleges, AL-Madinah AL-Munawarah City, P.O 41411, Box 167, Madina, Saudi Arabia.
- Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, 13713, Dariyah, Saudi Arabia.
- Pharmacy Practice and Clinical Pharmacy Department, Faculty of Pharmacy, Galala University- Ataka, Suez, 43511, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Assiut, 71524, Egypt.
Zitieren
APA
Saleh, A., Raslan, N. A., Selim, H. M. R. M., Ibrahim, S., Farghly, A. M., Shalkami, A. S., Salama, L. A., Elhusseiny, S. M., Hafez, S. M., Mahmoud, N. A., Alwakeel, A. I., Ali, S. O., Elsabbagh, S. A., Fouda, M. S., & El-Dessouki, A. M. (2026). Mechanistic insights into the hepatoprotective role of rabeprazole against cyclophosphamide-induced hepatotoxicity via AMPK/SIRT1 activation and suppression of TLR4/NF-κB and MAPK pathways. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04577-y
Vancouver
Saleh A, Raslan NA, Selim HMRM, Ibrahim S, Farghly AM, Shalkami AS, et al. Mechanistic insights into the hepatoprotective role of rabeprazole against cyclophosphamide-induced hepatotoxicity via AMPK/SIRT1 activation and suppression of TLR4/NF-κB and MAPK pathways. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04577-y
BibTeX
@article{Saleh2026,
author = {Saleh, Asmaa and Raslan, Nahed A and Selim, Heba Mohammed Refat M and Ibrahim, Samar and Farghly, Ahmed Mohamed and Shalkami, Abdel-Gawad S and Salama, Lamiaa A and Elhusseiny, Shaza M and Hafez, Shaimaa M and Mahmoud, Nihal A and Alwakeel, Asmaa I and Ali, Shimaa O and Elsabbagh, Sherif A and Fouda, Manar Seleem and El-Dessouki, Ahmed M},
title = {Mechanistic insights into the hepatoprotective role of rabeprazole against cyclophosphamide-induced hepatotoxicity via AMPK/SIRT1 activation and suppression of TLR4/NF-κB and MAPK pathways},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-025-04577-y}
}
EUVIMED